^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    luvometinib (FCN-159)

    i
    Company:
    Fosun Pharma
    Drug class:
    MEK1 inhibitor, MEK2 inhibitor
    Related drugs:
    Apply
    Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors (NCT06553365)
    Phase 2
    Cancer Institute and Hospital, Chinese Academy ...
    Not yet recruiting
    Last update posted :
    08/14/2024
    Initiation :
    08/15/2024
    Primary completion :
    07/31/2026
    Completion :
    07/31/2026
    NF2
    |
    luvometinib (FCN-159)
    MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) (NCT03932253)
    Phase 1
    Shanghai Fosun Pharmaceutical Industrial Develo...
    Suspended
    Last update posted :
    03/27/2024
    Initiation :
    03/21/2019
    Primary completion :
    04/30/2023
    Completion :
    04/30/2024
    NRAS • NF1
    |
    NRAS mutation
    |
    luvometinib (FCN-159)
    FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas (NCT05913037)
    Phase 3
    Shanghai Fosun Pharmaceutical Industrial Develo...
    Recruiting
    Last update posted :
    03/15/2024
    Initiation :
    06/20/2023
    Primary completion :
    06/30/2025
    Completion :
    06/30/2026
    NF1
    |
    luvometinib (FCN-159)
    Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1 (NCT04954001)
    Phase 2
    Shanghai Fosun Pharmaceutical Industrial Develo...
    Active, not recruiting
    Last update posted :
    10/17/2023
    Initiation :
    03/26/2021
    Primary completion :
    02/28/2025
    Completion :
    03/30/2025
    NF1
    |
    NF1 mutation
    |
    luvometinib (FCN-159)